Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Immunotherapy also appears to fuel tumor growth in these cancers
2021-03-24
(Press-News.org) New York, NY (March 24, 2021) -- Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount Sinai study published in Nature in March. NASH affects as many as 40 million people worldwide and is associated with obesity and diabetes.
The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH. They conducted a meta-analysis of three randomized phase 3 human trials that tested immunotherapy in HCC and found that in non-viral HCC cases, such as NASH-related HCC, therapy was significantly less effective than in viral-related cases.
In addition, this study found in animal models that immunotherapy with anti-PD1 inhibitors actually led to tumor growth instead of the intended effect of aiding the immune system to kill cancer cells and shrink the tumor. In these models, researchers identified immune cells called CD8+PD1+ as drivers of these phenomena. These cells were found to be dysfunctional and incapable of immunosurveillance.
"In addition to allowing clinicians to optimize treatment protocols based on the underlying liver disease, the knowledge obtained through this study will provide a backbone for the design of further combination treatments to overcome current limitations and improve survival for patients with these underlying liver conditions," said senior and co-corresponding author Josep Llovet, MD, PhD, Founder and Director of the Liver Cancer Program at The Tisch Cancer Institute and Professor of Medicine (Liver Diseases) at the Icahn School of Medicine at Mount Sinai. "These results also highlight the need for refined therapeutic strategies aimed at treating both the tumor as well as the microenvironment associated with distinct underlying liver disease."
Non-alcoholic fatty liver disease (NAFLD), a condition that is a precursor of NASH, is estimated to affect 25 percent of the population worldwide, and up to 20 percent of these patients will progress to having NASH. NASH is an emerging risk factor for HCC, which led to this study's investigation of immunotherapy's effects on NASH-related HCC. While immunotherapy has clinical benefit for hepatocellular carcinoma, this study's findings are important because a quarter of all HCC patients have NASH.
INFORMATION:
The meta-analysis in this study was conducted on three high-quality phase 3 trials that included more than 1,600 HCC patients treated with anti-PD1 immunotherapy. This study represents a major international collaborative effort from 110 investigators from 81 institutions.
Amaia Lujambio, PhD; Thomas Marron, MD, PhD; and Philipp Haber, MD, from Mount Sinai contributed significantly to this study and are also co-authors.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care--from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
ELSE PRESS RELEASES FROM THIS DATE:
2021-03-24
New scientific findings bring hope that early training during the presymptomatic phase could help individuals with Rett syndrome, a neurodevelopmental disorder, retain specific motor and memory skills and delay the onset of the condition. Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital reported in the journal Nature that, in a mouse model of Rett syndrome, intensive training beginning before symptoms appear dramatically improved the performance of specific motor and memory tasks and substantially delayed the appearance of symptoms.
The researchers propose that newborn genetic testing for Rett syndrome, followed by prompt intensive training in the skills that will be affected, such ...
2021-03-24
Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an experimental model, this type of immunotherapy actually promoted the development of liver cancer, as now reported in the journal Nature.
Liver cancer is the sixth most common type of cancer in the world, ...
2021-03-24
The heart of any computer, its central processing unit, is built using semiconductor technology, which is capable of putting billions of transistors onto a single chip. Now, researchers from the group of Menno Veldhorst at QuTech, a collaboration between TU Delft and TNO, have shown that this technology can be used to build a two-dimensional array of qubits to function as a quantum processor. Their work, a crucial milestone for scalable quantum technology, was published today in Nature.
Quantum computers have the potential to solve problems that are impossible to address with classical computers. Whereas current ...
2021-03-24
HOUSTON ? Overcoming previous technical challenges with single-cell DNA (scDNA) sequencing, a group led by researchers at The University of Texas MD Anderson Cancer Center has developed a novel method for scDNA sequencing at single-molecule resolution. This technique revealed for the first time that triple-negative breast cancers undergo continued genetic copy number changes after an initial burst of chromosome instability.
The findings, published today in Nature, offer an accurate and efficient new approach for sequencing hundreds of individual cancer cells while also providing novel insights into cancer evolution. These insights may explain why treatments are ...
2021-03-24
Joint press release by the German Cancer Research Center, University Medicine Mannheim, Heidelberg University Hospital, and the National Center for Tumor Diseases (NCT) Heidelberg
Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors. The vaccine proved to be safe and triggered the desired immune response in the tumor tissue, as the team now reports in the journal Nature.
Diffuse ...
2021-03-24
Researchers have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The vaccine product is currently being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against many more strains that current vaccines do not adequately cover.
A study detailing how the new flu vaccines were designed and how they protect mice, ferrets, and nonhuman primates appears in the March 24 edition of the journal Nature. This work was led by researchers at the University of Washington School of Medicine and the Vaccine
Research Center part of the National Institute of Allergy ...
2021-03-24
Many children of low-income families across the country do not have access to quality health care. Lack of health care can have a domino effect, affecting educational outcomes in the classroom.
School-based telehealth could offer a sustainable and effective solution, according to a new report in the Journal for Nurse Practitioners by Kathryn King Cristaldi, M.D., the medical director of the school-based telehealth program, and Kelli Garber, the lead advanced practice provider and clinical integration specialist for the program.
The program through the MUSC Health Center for Telehealth has effectively served over 70 schools across the state of South Carolina. Evaluating a child at school via telehealth ...
2021-03-24
Probiotics -- those bacteria that are good for your digestive tract -- are short-lived, rarely taking residence or colonizing the gut. But a new study from researchers at the University of California, Davis, finds that in breast milk-fed babies given the probiotic B. infantis, the probiotic will persist in the baby's gut for up to one year and play a valuable role in a healthy digestive system. The study was published in the journal Pediatric Research.
"The same group had shown in a previous study that giving breast milk-fed babies B. infantis had beneficial effects that lasted up to 30 days after supplementation, but this is the first study to show persistent colonization up to 1 year of age," said lead author Jennifer Smilowitz with the UC Davis Department ...
2021-03-24
Non-alcoholic steatohepatitis (NASH), often called 'fatty liver hepatitis', can lead to serious liver damage and liver cancer. A team of researchers at the Technical University of Munich (TUM) has discovered that this condition is caused by cells that attack healthy tissue - a phenomenon known as auto-aggression. Their results may help in the development of new therapies to avoid the consequences of NASH.
Fatty liver disease (NASH) is often associated with obesity. However, our understanding of the causes has been very limited. A team working with ...
2021-03-24
Rich false memories of autobiographical events can be planted - and then reversed, a new paper has found.
The study highlights - for the first time - techniques that can correct false recollections without damaging true memories. It is published by researchers from the University of Portsmouth, UK, and the Universities of Hagen and Mainz, Germany.
There is plenty of psychological research which shows that memories are often reconstructed and therefore fallible and malleable. However, this is the first time research has shown that false memories of autobiographical events can be undone.
Studying how memories are created, identified ...
LAST 30 PRESS RELEASES:
[Press-News.org] Liver cancer appears to be resistant to immunotherapy in patients with liver condition
Immunotherapy also appears to fuel tumor growth in these cancers
